We further observed that MET expression corresponds with high MYCN levels in MYCN amplified tumors (p = 0.027), disease relapse (p = 0.071), and worst outcome (p = 0.121) of NB patients in the Versteeg dataset (Figure 1G–I). This evidence concerns the gene MYCN and neuroblastoma.